Login / Signup

Higher throughput drug screening for rare respiratory diseases: readthrough therapy in primary ciliary dyskinesia.

Dani Do Hyang LeeDaniela CardinaleErsilia NigroColin R ButlerAndrew RutmanMahmoud R FassadRobert A HirstDale A MouldingAlexander AgrotisElisabeth ForsytheDaniel G PeckhamEvie RobsonClaire Mary SmithSatyanarayana SomavarapuPhilip L BealesStephen L HartSamuel M JanesHannah M MitchisonRobin KettelerRobert Edward HyndsChristopher O'Callaghan
Published in: The European respiratory journal (2021)
Initial analyses of ciliary ultrastructure, beat pattern and beat frequency in the 96-well transwell format ALI cultures indicate that a range of different PCD defects can be retained in these cultures. The screening system in our proof-of-principal investigation allowed drugs that induce translational readthrough to be evaluated alone or in combination with nonsense-mediated decay inhibitors. We observed restoration of basal body formation but not the generation of cilia in the patient's nasal epithelial cells in vitro. CONCLUSION: Our study provides a platform for higher throughput analyses of airway epithelia that is applicable in a range of settings and suggests novel avenues for drug evaluation and development in PCD caused by nonsense mutations.
Keyphrases
  • heart rate
  • case report
  • high throughput
  • adverse drug
  • emergency department
  • mesenchymal stem cells
  • cell therapy
  • smoking cessation
  • electronic health record